Bellicum Pharmaceuticals (STU:BPXA) Interest Expense : €0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Bellicum Pharmaceuticals's interest expense for the three months ended in Sep. 2023 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Bellicum Pharmaceuticals's Operating Income for the three months ended in Sep. 2023 was € -0.73 Mil. Bellicum Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was € 0.00 Mil. Bellicum Pharmaceuticals has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Bellicum Pharmaceuticals Interest Expense Historical Data

The historical data trend for Bellicum Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Interest Expense Chart

Bellicum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-3.69

-3.85

-2.19

Bellicum Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Bellicum Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Bellicum Pharmaceuticals (STU:BPXA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bellicum Pharmaceuticals's Interest Expense for the three months ended in Sep. 2023 was €0.00 Mil. Its Operating Income for the three months ended in Sep. 2023 was €-0.73 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2023 was €0.00 Mil.

Bellicum Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Bellicum Pharmaceuticals had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Bellicum Pharmaceuticals Inc has no debt.

Bellicum Pharmaceuticals (STU:BPXA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (STU:BPXA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

BLCM:USA

Address

3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098

Website

https://www.bellicum.com

Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.

Bellicum Pharmaceuticals (STU:BPXA) Headlines

No Headlines